Julia Owens: A Deep Dive Into Stroke Care and Basking Bio’s Innovative Programs
Julia Owens, Chief Executive Officer at Basking Biosciences Inc, reposted from Basking Biosciences, Inc. on LinkedIn:
”I have long admired Josh Schimmer‘s biotech insights and wit, so I was thrilled when he wanted to learn more about our work at Basking Bio.
I hope you will listen to this webinar where Josh and Alexa dig into the background of stroke care and our innovative programs with their usual probing questions.”
Quoting Basking Biosciences, Inc.‘s post:
”We had the privilege of joining Josh Schimmer and Alexa Deemer Conzola at Cantor Fitzgerald for a deep dive into acute ischemic stroke and the science behind our lead program, BB-031.
In the recording below, our CEO, Julia Owens, and Co-founder and Chief Scientific Officer, Dr. Shahid Nimjee, walk through the stroke treatment landscape, why targeting von Willebrand Factor represents a fundamentally different approach, and where BB-031 stands in its clinical development.
Thank you, Josh and the Cantor team, for the opportunity to share our story with your audience.
Stay updated with Hemostasis Today.
-
Sep 29, 2026, 19:00Caitlin Raymond: Can Artificial Blood Solve Blood Supply Shortages?
-
Sep 29, 2026, 18:51Chaza Alaji: Dyslipidemia, Thrombosis and the DIC Diagnostic Trap
-
Sep 29, 2026, 17:31Rajnikant Patel: Bridging Ayurvedic Concepts and Modern Toxin-Mediated Disease
-
Sep 29, 2026, 17:13Nicholas Lang։ A Meaningful Case of Immune Thrombocytopenia
-
Sep 29, 2026, 16:55Ayatullah Gamal Wahab: When the CBC Lies
-
Sep 29, 2026, 16:35Jonathan Douxfils: Navigating the VTE Risk Continuum in Reproductive Medicine
-
Sep 29, 2026, 16:35Chaima Rajeh: Types of Anemia and Their Laboratory Features
-
Sep 29, 2026, 16:27Scott Isaacs: How GLP-1 RAs Target Systemic Inflammation to Drive Cardio, Autoimmune, and Gut Health
-
Sep 29, 2026, 16:21Yitshak Kreiss: From Treating Patients to Defining the Standard of Knowledge